Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Meningiomas in 2009

Controversies and Future Challenges

Campbell, Belinda A., MBBS, FRANZCR*; Jhamb, Ashu, MBBS, FRANZCR; Maguire, John A., MBBCh, BAO, FRCP(C); Toyota, Brian, MD, CM, FRCSC§; Ma, Roy, MD, FRCPC*

American Journal of Clinical Oncology: February 2009 - Volume 32 - Issue 1 - p 73-85
doi: 10.1097/COC.0b013e31816fc920
Review Article
Buy

Meningiomas are the most common intracranial primary neoplasm in adults. Over recent years, interest in this clinically diverse group of tumors has intensified, bringing new questions and challenges to the fore, particularly in the fields of epidemiology, radiology, pathology, genetics, and treatment. Interest in modern meningioma research has been stimulated by the high tumor prevalence and the advances in technology. The incidence of meningiomas is climbing, and may indicate increased exposure to environmental risk factors or more sensitive diagnostic modalities. Technological advances have dramatically improved radiologic imaging and radiotherapy treatments, and further refinements are under investigation. Furthermore, the current era of tumor genetics and molecular biology is challenging translational researchers to discover new, targeted, therapeutic agents. This review is an update on the recent advances in the understanding of meningiomas and their management, and highlights pertinent research questions to be addressed in the future.

From the *Department of Radiation Oncology, Vancouver Cancer Centre, BC Cancer Agency; †Department of Radiology; ‡Division of Neuropathology, Department of Pathology and Laboratory Medicine; and §Division of Neurosurgery, Department of Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.

Reprints: Belinda Campbell, MBBS, FRANZCR, Department of Radiation Oncology, Vancouver Cancer Centre, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. E-mail: bcampbell3@bccancer.bc.ca.

© 2009 Lippincott Williams & Wilkins, Inc.